A tale of two tkis. Lorlatinib prevents new brain Mets. Based on intracranial Duration of Response neladalkib (admittedly in later line) doesn’t show the same flat line. Anti-ntrk’s cns protective effect separate from driver oncogene status is writ large. Still hiding in plain sight
